Bright Minds Biosciences (DRUG) stock

Market cap $497M

$50.69
+3.01%

Market closed. Prices as of Friday's close.

Not scored

Breakaway doesn't score DRUG. It is too thinly traded for a fair Quality Score.

Healthcare · Biotech

Follow DRUG's trial news. Pro members can get an alert when Bright Minds Biosciences files news, and see its trials, share raises, and its CEO's filings.

Get an optional alert when DRUG files news on its trialsSee it live, free for 24 hours. No account needed. Then keep going with a free account.

We do the work for you. 3,243 stocks are scored and ranked, every 15 seconds while the market is open. Pro members see it live. So can you, free, with no account.

What's next for DRUG

From Bright Minds Biosciences’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.

Its trials

A trial underway
2-Part Study to Assess Efficacy, Safety and Tolerability of BMB-101 for the Treatment of Patients With Prader-Willi Syndrome.Phase 2 · Not yet recruiting · 16 people · main data estimated Nov 2026 · NCT07266324

1 more trial, 44 filings, for Pro members.

Dilution on the horizon

  • Shelf registration (F-3, filed Aug 26, 2025)
  • At-the-market share sales program (F-3, filed Aug 26, 2025)

A shelf lets a company sell shares later; an at-the-market program sells them into the market over time. Neither is a sale by itself.

For Pro members: 1 raise and its amount, and the share count against a year ago.

Insiders

No open-market buys or sales by its officers or directors in their filings of the last year.

From their own Form 4 filings: buys and sales in the market, not awards or shares withheld for tax.

For Pro members: every trade.

Get an optional alert when DRUG files news on its trialsSee it live, free for 24 hours. No account needed. Then keep going with a free account.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.

DateStockDrug

8 more FDA dates and 114 trial data dates in the next 60 days. Pro members see every one, with the cash against its date and an optional alert before it. Get in free →

DRUG's latest filings

19 more filings in the last year, for Pro members

From SEC EDGAR, as filed. Each opens the filing on the SEC's site.

Why DRUG isn't scored

The Quality Score reads US-listed stocks worth $50M or more that trade at $1 or more and 300,000 shares a day. DRUG trades about 92,000 shares a day. A stock that clears every mark is scored from the next weekly rebuild.

Straight Answers

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, trial included, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Where does the data come from?

Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.

Do I need an account?

Not for the first 24 hours. Tap any green button and you're in, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.

Is this investment advice?

No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.

The price on this page is delayed at least 15 minutes. The share count and the filings are shown as filed.